Hydroxystenozole
![]() | |
| Identifiers | |
|---|---|
| |
| Synonyms | NSC-43194; 17α-Methyl-2'H-androsta-2,4-dieno[3,2-c]pyrazol-17β-ol; 17β-Hydroxy-17α-methylandrost-4-eno[3,2-c]-pyrazole |
| CAS Number |
5697-57-4 |
| PubChem (CID) | 238684 |
| ChemSpider |
208502 |
| UNII |
5OW19U0553 |
| ChEBI | CHEBI:79555 |
| ChEMBL |
CHEMBL2105010 |
| Chemical and physical data | |
| Formula | C21H30N2O |
| Molar mass | 326.48 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Hydroxystenozole (INN), also known as 17α-methylandrost-4-eno[3,2-c]pyrazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of testosterone that was described in the literature in 1967 but was never marketed.[1] It is closely related to stanozolol (17α-methyl-5α-androstano[3,2-c]pyrazol-17β-ol), differing from it only in hydrogenation (i.e., double bonds and their placement).
References
- ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 668. ISBN 978-1-4757-2085-3.
This article is issued from Wikipedia - version of the 12/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
